No profile data available.
Neurocrine Biosciences, Inc. (NBIX) is a healthcare company in the brain and nerve treatment drugs industry, based in San Diego, United States, with about 2,500 full-time employees.
It reported revenue of $2.86 billion for fiscal year 2025, up 21.2% from fiscal year 2024, and net income of $478.60 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $959.00 million, up 39.5% from a year before. Its market capitalization was $14.48 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
Neurocrine Biosciences reported $2.86 billion in revenue for fiscal year 2025, up 21.2% from $2.36 billion in fiscal year 2024. In Q2 2026 revenue was $959.00 million.
$14.48 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include argenx SE (ARGX), Biogen Inc. (BIIB), Jazz Pharmaceuticals plc (JAZZ), Axsome Therapeutics, Inc. (AXSM).